Stock Events

Ocular Therapeutix 

$8.13
34
+$0.53+6.97% Friday 20:00

Statistics

Day High
8.22
Day Low
7.62
52W High
11.31
52W Low
2
Volume
2,165,610
Avg. Volume
2,868,214
Mkt Cap
1.26B
P/E Ratio
-7.01
Dividend Yield
-
Dividend
-

Earnings

7MayConfirmed
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
-0.39
-0.32
-0.26
-0.19
Expected EPS
-0.19
Actual EPS
-0.28

People Also Follow

This list is based on the watchlists of people on Stock Events who follow OCUL. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Regeneron Pharmaceuticals
REGN
Mkt Cap111.64B
Regeneron Pharmaceuticals competes with Ocular Therapeutix in the eye care market, particularly in treatments for eye diseases and conditions.
Novartis
NVS
Mkt Cap236.8B
Novartis provides advanced eye care treatments, including gene therapy for retinal diseases, directly competing with Ocular Therapeutix's eye disease treatments.
Abbvie
ABBV
Mkt Cap295.34B
AbbVie, through its acquisition of Allergan, competes in the ophthalmology space, particularly in treatments for eye conditions that overlap with Ocular Therapeutix's portfolio.
Bausch Health Companies
BHC
Mkt Cap2.61B
Bausch Health Companies, through its eye health division, offers products that compete across a broad range of eye conditions treated by Ocular Therapeutix.
Johnson & Johnson
JNJ
Mkt Cap352.53B
Johnson & Johnson, through its Vision Care division, competes in the market for eye health, offering products that can overlap with Ocular Therapeutix's therapeutic areas.
Pfizer
PFE
Mkt Cap158.95B
Pfizer has a presence in the ophthalmology market, competing indirectly with Ocular Therapeutix through its various treatments for eye diseases.
Regenxbio
RGNX
Mkt Cap536.89M
REGENXBIO is involved in gene therapy for eye diseases, representing a direct competitor to Ocular Therapeutix's approach to treating similar conditions.
EyePoint Pharmaceuticals
EYPT
Mkt Cap442.2M
EyePoint Pharmaceuticals focuses on sustained release drug delivery for eye diseases, directly competing with Ocular Therapeutix's drug delivery technology.

Analyst Ratings

15.4$Average Price Target
The highest estimate is $22.
From 5 ratings within the last 6 months. This is not an investment recommendation.
Buy
80%
Hold
20%
Sell
0%

About

Health Technology
Pharmaceuticals: Other
Pharmaceuticals: Major
Manufacturing
Pharmaceutical Preparation Manufacturing
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology. The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cataract surgery; and DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing OTX-TKI, an axitinib intravitreal implant that is in phase 1 clinical trials for the treatment of wet age-related macular degeneration and other retinal diseases; OTX-TIC, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the Company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC, as well as a discovery collaboration with Mosaic Biosciences to identify new targets and therapeutic agents for the treatment of dry age-related macular degeneration (dMAD). Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
Show more...
CEO
Antony Mattessich
Employees
267
Country
US
ISIN
US67576A1007
WKN
000A1180P

Listings